Home・Aandelen Lijst・Xencor Inc

Xencor Inc

Gesloten

SectorGezondheidszorg

19.36 -0.62

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

18.87

Max

19.85

Belangrijke statistieken
By Trading Economics
Inkomsten	-214M -129M
Verkoop	-24M 4.5M
EPS	-1.71
Winstmarge	-2,854.65
Werknemers	260
EBITDA	-127M -121M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+23.4% upside

Dividenden
By Acuity
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	404M 1.4B
Vorige openingsprijs	19.98
Vorige sluitingsprijs	19.36

Nieuwssentiment

By Acuity

50%

163 / 340 Rangschikking in Healthcare

Xencor Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 jul 2026, 19:11 UTC

Xencor Inc shares are lower in Friday's session, reflecting broader market trends. No specific news was identified to explain the price movement.

22 jul 2026, 20:06 UTC

Xencor Inc shares are lower today, retracing from an earlier peak. Broader market sentiment is affected by uncertainty ahead of the Federal Reserve meeting.

21 jul 2026, 19:02 UTC

Social Media

Xencor Inc. shares reached a new 52-week high, driven by developments in RCC related to ENPP3 and immuno-oncology efforts involving TL1A.

20 jul 2026, 19:41 UTC

Social Media

Xencor Inc's shares are higher as clinical results are accepted for presentation at the ESMO conference, with a Phase 3 trial planned for 2027.

Peer Vergelijking

Prijswijziging

Xencor Inc Prognose

Koersdoel

By TipRanks

23.4% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 24.1 USD 23.4%

Hoogste 38 USD

Laagste 13 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Xencor Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Xencor Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

163 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.